High dose chemotherapy in ovarian cancer

International Journal of Gynecological Cancer

Volumn 11, Issue SUPPL. 1, 2001, Pages 64-67

  Pujade Lauraine, E ^a   Cure H ^a   Battista, C ^a   Guastalla, J P ^a   Chiurazzi, B ^a   Fabbro, M ^a   Tubiana Mathieu, N ^a   Bourgeois, H ^a   Lioure, B ^a   Paraiso, D ^a   Lotz, J P ^a  

^a HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; MESNA; PLATINUM DERIVATIVE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG MEGADOSE; HEMATOPOIETIC STEM CELL; OVARY CANCER; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CISPLATIN; CLINICAL TRIALS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; OVARIAN NEOPLASMS;

EID: 17844395693     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.2001.11(suppl.1)sup1064.x     Document Type: Conference Paper

References (20)

1. Dose intensity versus total dose of chemotherapy: An experimental basis
2. Importance of multiagent chemotherapy regimens in ovarian carcinoma: Dose intensity analysis
3. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer
4. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results
5. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer
6. Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer
7. How many more nails to seal the coffin of dose intensity?
8. A phase I clinical and pharmacokinetic of carboplatin and autologous bone marrrow support
9. High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer
10. High-dose melphalan and autologous marrow rescue in advanced epithelial ovarian carcinomas: A retrospective analysis of 35 patients treated in France
11. Salvage therapy for recurrent and refractory ovarian cancer with high-dose chemotherapy and autologous bone marrow support: A Gynecologic Oncology Group pilot study
12. Phase I clinical and pharmacokinetic study of high-dose mitoxantrone combined with carboplatin, cyclophosphamide, and autologous bone marrrow rescue: High response rate for refractory ovarian carcinoma
13. Tandem high-dose chemotherapy with ifosfamide, carboplatin, and teniposide with autologous bone marrow transplantation for the treatment of poor prognosis common epithelial ovarian cancer
14. Phase II study of "dose-dense" high-dose chemotherapy with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer
15. High-dose chemotherapy as first line treatment in ovarian cancer: A phase II study
16. Acute in vivo resistance in high-dose therapy
17. High-dose chemotherapy with peripheral blood stem cell transplantation (PBSCT) in ovarian cancer
18. High-dose chemotherapy and autologous stem-cell transplantation for ovarian cancer: An autologous blood and marrow transplant registry report
19. High dose chemotherapy with autologous stem cell support in the treatment of patients with ovarian carcinoma: Long term results for 105 patients
20. Phase III randomized trial of high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) support as consolidation in patients (pts) with responsive low-burden advanced ovarian cancer (AOC): Preliminary results of a GINECO/FNCLCC/SFGM-TC study